EdgeTestMarket TodayOptions TodayIPO
Start free

AGARWALEYEDr. Agarwal's Health Care Limited

Rs 475.25▲ +0.28%
Market closedEquity EOD 26 Oct
Compare
52-week rangeThe lowest and highest prices the stock traded at over the last year, from each day's intraday low and high. The marker is today's close: 0% means it sits at the year's low, 100% at the high. It describes where the price is, not where it is going.44.5% up the range
Rs 401Rs 568
AGARWALEYE price
Daily candles, adjusted for splits and bonus issues so a corporate action does not show as a crash. Pick a window from one month to the full history, add indicators, or open it full screen.
EOD 26 Oct
IndicatorsVolume

Loading AGARWALEYE price...

At a glance
Each figure is shown against the company's sector (the track: the dot is this company, the tick is the sector middle) and, where we hold the yearly filings, against its own recent years (the small trend line).
Market capWhat the whole company is worth on the stock market today: share price times the number of shares. It measures size, not quality.
Rs 15,065 cr
Larger than 58% of 19 peers
sector middle Rs 9,487 cr
P/EPrice to earnings: how many rupees investors pay for each rupee of profit the company made over the last twelve months. Compare it with similar companies rather than reading it alone.
102.2x
Higher than 76% of 17 peers
sector middle 52.9x
Price to bookPrice to book: the share price divided by the shareholders' money per share in the latest balance sheet. Around 1 means the market values the company close to its book value.
7.4x
Higher than 72% of 18 peers
sector middle 5.6x
ROEReturn on equity: the year's profit as a percentage of the shareholders' money in the business. It shows how much the company earns on what its owners have put in.
8.7%
Lower than 65% of 17 peers
sector middle 12.1%
ROCEReturn on capital employed: operating profit as a percentage of all the long-term money in the business, owners' and lenders'. It shows how well the company uses its capital, whatever the mix of debt.
9.7%
Lower than 72% of 18 peers
sector middle 12.4%
FY25 8.4%FY26 9.7%
Debt to equityBorrowings divided by shareholders' money. 0 means no borrowings; 1 means it owes as much as its owners have put in. Not shown for banks and lenders, whose borrowing is their business.
0.07
Lower than 78% of 18 peers
sector middle 0.26
FY25 0.13FY26 0.07
Dividend yieldDividends paid over the last year as a percentage of the company's market value: roughly what Rs 100 of shares paid out in cash.
0.0%
Lower than 67% of 18 peers
sector middle 0.1%
Sales growthHow much the latest quarter's sales grew against the same quarter a year earlier.
+26.0%
Higher than 62% of 16 peers
sector middle +19.4%

Peers are the listed companies in the exchange's own industry group: Hospital. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.

What the numbers say
Short lines written by fixed rules from the company's own filings and shareholding. A line appears only when the figures cross the rule (for example sales growing three years running), and each names the numbers behind it. Nothing here is a view on whether to own the share.

Latest quarterIn the quarter to June 2026 (results filed 4 Aug 2026), sales rose 26.0% from a year earlier to Rs 614 cr and profit rose 44.6% to Rs 55.0 cr.

Nothing in the filings we hold crosses one of our rules yet. Each rule needs a few complete years of results, so recently listed companies often show nothing here.

Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.

How the share moved on results
For each quarterly result we hold: the change from the share's close on the last trading day before the filing to its close on the first trading day after it. Results can land during market hours or after the close, and this window covers both. It shows what happened, not what will happen next time.

Over the last 7 results, the share rose on 4 and fell on 3, and moved by 3% or more on 4.

Q3 FY25Q2 FY26Q1 FY27

Q1 FY27: results filed 4 Aug 2026. The share went from its close on 3 Aug 2026 to its close on 5 Aug 2026 +7.81%.

Fundamentals
Trailing-twelve-month valuation, margins and growth from the company's own filings.
as of 2026-06-30
P/E (TTM)
102.2
PEG
2.29
EPS (TTM)
Rs 4.7
Net margin
8.4%
Rev growth YoY
+25.97%
Profit growth YoY
+44.56%
TTM revenue
Rs 2,207 Cr
TTM net profit
Rs 185 Cr
Health check, year by year
Returns and debt for each financial year from the March balance sheet, each row coloured against this company's own usual level.
MeasureFY25FY26
ROCEOperating profit as a percentage of all long-term capital, owners' and lenders'.8.4%9.7%
Debt to equityBorrowings divided by shareholders' money. Lower is safer.0.13x0.07x

Each row is coloured against this company's own usual level, not against other companies: green is better than its middle year, red worse, plain is close to it. ROE, ROCE and debt rows start once the filings carry a full balance sheet (FY22 at the earliest).

What it owns, and how that is paid for
Straight from the March balance sheet in the company's annual filing. Both bars are the whole balance sheet: what the company owns, and where the money for it came from.
as at 2026-03-31

At FY26 it owned Rs 3,942 Cr of assets. Its owners funded 54% of that and borrowings 4%.

What it owns
29%
29%
28%
Plant, property and projects1,161 Cr
Goodwill and intangibles1,144 Cr
Investments152 Cr
Inventory94 Cr
Owed by customers161 Cr
Cash and bank129 Cr
Everything else1,101 Cr
How that is paid for
54%
38%
Shareholders2,120 Cr
Borrowings157 Cr
Owed to suppliers149 Cr
Other liabilities1,516 Cr
Cash and equivalents
Rs 91 Cr
Net debt
Rs -86 Cr
more cash than debt
Current ratio
1.24x
short-term assets per rupee due soon
Book value / share
Rs 64
Return on assets
4.7%
EV / EBITDA
24.3x

From the March balance sheet in the company's annual filing (2026-03-31). Each bar is the full balance sheet; "everything else" is what the filed total leaves after the named lines.

Where the cash went
Profit is an accounting figure; cash flow is what actually moved. Cash from running the business, plus or minus what was spent on or received from investments, plus or minus what came from or went to lenders and shareholders, equals the change in cash.

In FY26 the business itself brought in Rs 519 Cr, spent Rs 448 Cr on plant and equipment, and cash fell by Rs 10 Cr over the year.

From running the business
+519 Cr
Spent on or received from investing
-308 Cr
From or to lenders and shareholders
-220 Cr
Net change in cash
-10 Cr
Cash from operations for every Rs 100 of profit
Rs 327
FY25
Rs 309
FY26

Rs 100 or more means every rupee of reported profit arrived as cash.

Full financial year to 2026-03-31, from the company's cash flow statement.

Against its sector
Where this stock sits within its own sector on each measure. The marker is its position in the peer group and the notch is the sector median. A position is a fact about the cohort, not a view on the stock.
Hospital · 28
P/E102.2vs 52.93 median
Cheapest: JLHL 8.84Priciest: LOTUSEYE 1419.5
Net margin8.39%vs 10.23% median
Lowest: LOTUSEYE 0.26%Highest: MAXHEALTH 16.73%
Revenue growth25.97%vs 19.39% median
Lowest: INDRAMEDCO 11.26%Highest: NH 78.05%
Compared against
AATMAJABHAPOLLOHOSPARTEMISMEDASTERDMDRAGARWQFORTISGKSLGPTHEALTHHCGINDRAMEDCOJLHLKIMSKMCSHILLOTUSEYEMAITREYAMANIPALHOSMAXHEALTHMEDANTAMOMSBELIEFNEPHROCARENHPARKHOSPSRAINBOWSANGANISHALBYUNIHEALTHYATHARTH

Median rather than average, so one loss-making or one very expensive peer cannot drag the reference. Valuation is shown without a colour verdict: a higher multiple can mean expensive, or faster growth expected, and only you can decide which.

Peers side by side
Every company in the same NSE industry group that we hold figures for, largest first. Tap any heading to sort by it. The same figures as the At a glance tiles, worked out the same way for every company.
Hospital · 20 shown
Company
APOLLOHOSP
Apollo Hospitals Enterprise Limited
1.13 L cr54.0x11.9x21.8%19.5%0.578.2%+20.6%0.26%
MAXHEALTH
Max Healthcare Institute Limited
81,266 cr56.0x7.6x13.6%12.7%0.3216.7%+16.7%0.18%
MANIPALHOS
Manipal Health Enterprises Limited
73,581 cr--------
FORTIS
Fortis Healthcare Limited
55,467 cr52.9x5.6x10.5%12.0%0.2811.3%+17.5%0.14%
NH
Narayana Hrudayalaya Ltd.
33,971 cr41.4x7.5x18.0%11.4%1.079.0%+78.0%0.27%
ASTERDM
Aster DM Quality Care Limited
33,523 cr104.9x7.3x7.5%10.2%0.157.4%+21.6%0.16%
MEDANTA
Global Health Limited
32,575 cr58.6x8.2x13.9%15.1%0.3011.8%+26.5%0.04%
KIMS
Krishna Institute of Medical Sciences Limited
28,123 cr131.3x12.5x7.6%8.2%1.274.6%+35.3%0.74%
AGARWALEYE
Dr. Agarwal's Health Care Limited
15,065 cr102.2x7.4x8.7%9.7%0.078.4%+26.0%0.01%
RAINBOW
Rainbow Childrens Medicare Limited
11,802 cr41.3x7.2x17.4%16.8%0.0015.9%+33.2%0.26%
PARKHOSPS
Park Medi World Limited
9,487 cr-4.7x-18.1%0.11--0.00%
YATHARTH
Yatharth Hospital & Trauma Care Services Limited
8,924 cr49.3x4.9x9.7%11.0%0.1413.1%+52.3%0.00%
HCG
Healthcare Global Enterprises Limited
8,508 cr367.6x6.4x2.4%6.9%0.651.3%+13.4%0.00%
ARTEMISMED
Artemis Medicare Services Limited
4,547 cr40.0x4.9x12.1%13.7%0.2410.2%+12.7%0.13%
INDRAMEDCO
Indraprastha Medical Corporation Limited
2,750 cr20.8x3.7x25.4%30.7%0.0012.3%+11.3%1.49%
JLHL
Jupiter Life Line Hospitals Limited
1,658 cr8.8x1.1x12.1%13.8%0.3312.0%+18.2%0.40%
GKSL
Gujarat Kidney And Super Speciality Limited
1,400 cr70.8x5.5x6.6%8.6%0.0616.6%-0.00%
SHALBY
Shalby Limited
1,240 cr32.9x1.2x3.7%7.9%0.543.2%+11.7%0.00%
GPTHEALTH
GPT Healthcare Limited
1,066 cr22.6x4.0x17.6%16.4%0.069.6%+17.8%1.92%
LOTUSEYE
Lotus Eye Hospital and Institute Limited
236 cr1419.5x3.9x0.2%1.1%0.190.3%+26.2%0.00%

Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.

The business
Sales and net profit from the company's own filings, by financial year or by quarter. Hover any bar for that period's complete figures including operating margin and the change against the comparable earlier period. The single TTM figure above is the sum of the last four quarters.
7 quarters
RevenueRs 614 Cr
Net profitRs 55 Cr
Dec 247 quarters filedJun 26

Each bar is one quarter as filed with the exchange, newest on the right, so the seasonal shape of the business is visible rather than smoothed away. Hover any quarter for its full figures and the change against the same quarter a year earlier. Revenue and profit are drawn on separate scales because they differ by an order of magnitude; reading one against the other would be misleading.

Large institutional deals
Bulk and block deals reported by the exchange, where a single large trade is disclosed along with the counterparty's name. Only deals above the exchange's disclosure threshold appear here.
last 8
DatePartySideQtyPriceValue
2026-08-12HYPERION INVESTMENTS PTE. LTD.SELL2,41,60,000501.03Rs 1,210.49 Cr
2026-08-12CLAYMORE INVESTMENTS (MAURITIUS) PTE.LTD.SELL1,59,00,000501.54Rs 797.45 Cr
2026-08-12ICICI PRUDENTIAL MUTUAL FUNDBUY62,11,813501Rs 311.21 Cr
2026-08-12POLAR CAPITAL FUNDS PLC-HEALTHCARE OPPORTUNITIES FUNDBUY36,26,410501Rs 181.68 Cr
2026-08-12INVESCO MUTUAL FUNDBUY35,65,443504.64Rs 179.93 Cr
2026-08-12MARWADI CHANDARANA INTERMEDIARIES BROKERS PRIVATE LIMITEDBUY19,59,808502.46Rs 98.47 Cr
2026-08-12ALLIANZ GLOBAL INVESTORS GMBH ACTING ON BEHALF OF ALLIANZ EEE FONDSBUY17,72,127501Rs 88.78 Cr
2026-08-12MARWADI CHANDARANA INTERMEDIARIES BROKERS PRIVATE LIMITEDSELL6,50,808510.96Rs 33.25 Cr
Technical snapshot
Momentum, trend and delivery-based conviction from the actual price and volume history.
EOD 26 Oct
RSI (14) - momentum
45.2Neutral
0 oversold3070overbought 100
Delivery % - genuine buying vs churn
56.5%Near average
today 56.5%20d avg 53.6%

The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.

vs 50-DMA
-3.87%
vs 200-DMA
+1.08%
1-month
-3.95%
3-month
-0.76%
1-year
-12.23%
Realized vol (30d)
20.6%
Insider trading disclosures
Promoter, director and other insider trades in the company's own shares, as disclosed to the exchange under SEBI's insider-trading regulations - usually within a few days of the transaction.
last 18 months

Insider trading data unavailable.

Recent announcements
The company's own filings to the exchange - results, board meetings, investor calls - with a link to the source document.
last 6 months

Announcements unavailable.

Want to test a strategy on AGARWALEYE?

Backtest an equity strategy on real market data, free - no card needed.

Start free

Equity price, fundamentals and realized volatility are end-of-day / quarterly from real market data. The option chain (PCR, max pain, expected move, IV, OI) is live from the exchange during market hours; outside them it shows the last session's close. Shareholding, insider trades and announcements are the company's own exchange filings. Analysis only, not investment advice.